

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 7/16	A1	(11) International Publication Number: WO 99/32073 (43) International Publication Date: 1 July 1999 (01.07.99)
<p>(21) International Application Number: PCT/EP98/07999</p> <p>(22) International Filing Date: 9 December 1998 (09.12.98)</p> <p>(30) Priority Data: 97811012.0 22 December 1997 (22.12.97) EP 98810616.7 2 July 1998 (02.07.98) EP</p> <p>(71) Applicant (for all designated States except US): CIBA SPECIALTY CHEMICALS HOLDING, INC. [CH/CH]; Klybeckstrasse 141, CH-4057 Basel (CH).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BASCHONG, Werner [CH/CH]; Maiengasse 27, CH-4056 Basel (CH). HÜGLIN, Dietmar [DE/DE]; Dorfstrasse 3, D-79591 Eimeldingen (DE). FANKHAUSER, Peter [CH/CH]; Hauptstrasse 65, CH-4107 Ettingen (CH). HEINEMANN, Gerd [DE/DE]; Untere Biefangstrasse 31, D-79418 Schliengen (DE).</p> <p>(74) Common Representative: CIBA SPECIALTY CHEMICALS HOLDING INC.; Patentabteilung, Klybeckstrasse 141, CH-4057 Basel (CH).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: USE OF POLYANIONIC AND POLYANIONICALLY-DERIVATISED NATURAL POLYSACCHARIDES FOR INHIBITING ALKALINE PHOSPHATASE</p> <p>(57) Abstract</p> <p>A description is given of the use of polyanionic and polyanionically-derivatised natural polysaccharides or non-derivatised natural polysaccharides for inhibiting alkaline phosphatase and of oral compositions for preventing bacterial plaque, which comprises (a) 0 to 10 % by weight of at least one linear molecularly dehydrated polyphosphate salt, and (b) 0.0001 to 5 % by weight of a polyanionic or polyanionically-derivatised natural polysaccharide.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Use of polyanionic and polyanionically-derivatised natural polysaccharides for inhibiting alkaline phosphatase

The present invention relates to the use of polyanionic and polyanionically-derivatised natural polysaccharides or non-derivatised natural polysaccharides for inhibiting alkaline phosphatase as well as to oral preparations comprising these compounds.

In the dental area there is often the problem of formation of plaque (tartar, calculus) produced by bacterial adhesion to natural or artificial teeth or to the gum and promoting the development of caries and gum diseases such as parodontosis. Tartar is understood to mean deposits which form at the margin of the gum on the surface of the teeth. These deposits consist both of inorganic material - in particular calcium hydrogenoxylapatite (HAP) - and of organic components, such as epithelial cells, food particles, saliva sediments and different kinds of microorganisms.

This whitish, yellowish or often blotchy tartar is undesirable not only because of its appearance but mainly because it gives constant occasion to irritations of the oral mucosa and to the development of gingivitis and diseases of the teeth and teeth socket. Such deposits are prevented on the one hand by daily dental care and by the concomitant microdecalcification. In addition, it is usually necessary to have the dentist remove tartar mechanically from time to time.

Safe and effective agents for inhibiting tartar formation are, for example, the water-soluble, molecularly dehydrated polyphosphates known as sequestrants and chelating agents, such as hexametaphosphates, tripolyphosphates and pyrophosphates, which prevent the formation of HAP (cf. US-A-4,515,722). In oral application, however, the effect of these compounds is significantly reduced by the saliva enzymes present in the mouth and throat area, such phosphate compounds being hydrolysed in particular by alkaline phosphatases.

US-A-5,094,844 proposes to reduce the deactivating effect of alkaline phosphatase, i.e. the hydrolysis of the linear molecularly dehydrated polyphosphates, by addition of an anionic polyvinyl phosphonate.

It is the object of this invention to provide further agents which reduce the negative effect of alkaline phosphatase.

Surprisingly, it has now been found that the use of polyanionic and polyanionically-derivatised natural polysaccharides or non-derivatised natural polysaccharides has an inhibiting effect on alkaline phosphatase.

Accordingly, this invention relates to the use of polyanionic and polyanionically-derivatised natural polysaccharides or non-derivatised natural polysaccharides for inhibiting alkaline phosphatase.

In particular, this invention relates to the use of polyanionic and polyanionically-derivatised natural polysaccharides for inhibiting alkaline phosphatase.

The polyanionic and polyanionically-derivatised natural polysaccharides used are preferably


- mucopolysaccharides and other polyanionic natural polysaccharides, such as hyaluronic acid or carageenan,
- polyanionic derivatives, for example sulfates, methylcarboxylates, phosphates etc. of natural, nonanionic polysaccharides, such as dextrans, xanthans, glucans.

Polyanionically-derivatised natural polysaccharides are preferably those compounds which contain phosphate groups, phosphonate groups or methylphosphonate groups, such as

- chitin derivatives, for example sulfochitins, carboxymethylchitins, phosphochitins or, in particular,
- chitosan derivatives, for example sulfochitosans, carboxymethylchitosans or, very particularly, phosphochitosans.


The polyanionic and polyanionically-derivatised natural polysaccharides used according to this invention preferably have a molecular weight of > 5000.

Preferred phosphochitosans are in particular phosphonomethylated chitosans corresponding to formula



wherein

R_1 is hydrogen or a radical of formula




R_2 is a radical of formula (1a);

X_1 and X_2 are each independently of the other hydrogen, C_1 - C_5 alkyl or an alkali ion or ammonium ion; and

n is 20 to 4000.

Very particularly preferred are phosphonomethylated chitosans of formula



wherein


X_1 and X_2 are as defined for formula (1).

Most interesting are those compounds of formula (1) or (2), wherein

X_1 and X_2 are each independently of the other alkali metal, and

n is 20 to 1000.

The non-derivatised natural polysaccharides used according to this invention are preferably glucans. It is preferred to use β -1,3-glucans corresponding to formula



wherein

n is a number corresponding to an average molecular weight (MW) in the range from $>5 \times 10^3$ to 10×10^{10} and, very particularly, from 10^5 to 10^8 .

It has also been found that the polyanionic and polyanionically-derivatised natural polysaccharides and the non-derivatised natural polysaccharides used according to this invention, in particular the phosphonomethylated chitosans of formulae (1) and (2) and the β -glucans of formula (3), inhibit the adhesion of microorganisms, in particular of anaerobic microorganisms, on solid surfaces, especially in holes, interspaces, deposits, pockets in the mouth and throat area, and that they thus reduce or inhibit the negative effects of these germs, in particular the formation of plaque and calculus, or dental decay, bad breath (malodor) and deposits on dentures.

These compounds can also detach the microorganisms from solid surfaces (desorption).

Forming complexes with the Zn, Sn and Mn, Al, Sb, Zr, La, Hf, Ta, Ir, Gd metals, these compounds are furthermore able to desensitise e.g. over-sensitivity on teeth.

The buffer capacity of the phosphonomethylated chitosan stabilises the intrabuccal pH and prevents hyperacidity and hence tooth decay.

In contrast to polyvinyl phosphonates and similar derivatives of synthetic polymers, the phosphonomethylated chitosans of formulae (1) and (2) and the glucans of formula (3) are compounds which are biocompatible and completely bio-degradable.

The preparation of these compounds is carried out by phosphonomethylation of chitosan in a manner known per se. Further details on their preparation may be found in EP-A-0,713,882.

In another of its aspects, this invention relates to an oral composition, which comprises

- (a) 0.01 to 10 % by weight, preferably 2 to 5 % by weight, of at least one linear molecularly dehydrated polyphosphate salt, and
- (b) 0.0001 to 5 % by weight of a polyanionic and polyanionically-derivatised natural polysaccharide.

The polyphosphate salts (= component (a)) used according to this invention, for example the hexametaphosphate, tripolyphosphate and pyrophosphate salts which are effective as active substance against the formation of bacterial plaque in the novel oral composition, are water-soluble alkali metal salts, such as the sodium, potassium or ammonium salts, and mixtures thereof. These compounds are known as agents preventing bacterial plaque from US-A-4,627,977 and 4,806,340.


Component (a) in the novel oral composition is preferably hexametaphosphate, tripolyphosphate, pyrophosphate or mixtures of these compounds.

The polyphosphates can comprise, for example, 2 to 120 phosphorus atoms and are used in the novel oral composition in amounts from 0.01 to 10 % by weight, preferably from 2 to 5 % by weight, based on the total weight of the composition.

Pyrophosphate is preferably used as a mixture of tetrapotassium pyrophosphate and tetrasodium pyrophosphate.

The novel composition may also contain antimicrobial active substances, for example phenol derivatives, diphenyl compounds, benzyl alcohols, chlorhexidine, C₁₂-C₁₄alkylbetaine, C₈-C₁₈fatty acid amidoalkylbetaine, amphoteric surfactants, trihalocarbanilides, quaternary ammonium salts and, very particularly, 2-hydroxydiphenyl ethers of formula

- 6 -



wherein

Y is chloro or bromo,

Z is SO₂H, NO₂ or C₁-C₄alkyl,

p is 0 to 3,

m is 0 to 3,



p is 0 or 1,

m is 0 or 1, and

n is 0 or 1.

Handwritten notes:
 R₂ H or allen
 R₃ H or alkyl
 R₄ → H
 R₅ → OH
 R₆ → H
 provided out by 1C+1a

Very particularly preferred compounds are those of formula



Handwritten notes:
 R₂ → H
 R₃ → Me
 R₄ → H
 R₅ → OH
 R₆ → Me

Handwritten notes:
 1, 2, 4, 5, 6, 7, 8, 9
 14, 15, 16, 17, 18
 19, 20, 21, 24, 27
 28, 29, 30, 31, 32

The novel oral composition can also comprise compounds releasing fluoride ions which are effective against caries formation, for example inorganic fluoride salts, such as sodium fluoride, potassium fluoride, ammonium fluoride or calcium fluoride, or organic fluoride salts, for example amine fluorides which are known under the tradename Olafleur. These compounds may be present in the novel composition in amounts of 0.005 to 3 % by weight, depending on solubility and kind of composition.

The novel oral composition is preferably liquid, for example in the form of a mouth wash or mouth rinse, the composition preferably being a 1:1 to 20:1, preferably a 2:1 to 10:1, mixture of water and alcohol.

The pH of the novel oral composition is 4.5 to 9, preferably 5.5 to 8.

The novel oral composition can also be in solid or pasty form, for example in the form of tooth powder, tooth tablet, toothpaste, tooth gel or tooth cream. Such a solid or pasty composition usually comprises an orally acceptable, water-insoluble polishing material. Examples of such polishing materials are water-insoluble metaphosphates, tricalcium phosphates, dehydrated dicalcium phosphates, calcium pyrophosphates, aluminium silicates, zirconium silicates, bentonite, or mixtures of these compounds. The polishing material is usually present in the solid or pasty composition in amounts of 10 to 90 % by weight, preferably of 10 to 75 % by weight.

The novel oral composition can also contain further materials, for example whitening agents, preservatives, silicones, chlorophyll compounds, other agents for the prevention of bacterial plaque, urea, diammonium phosphates, and mixtures thereof. These adjuvants are present in the novel compositions in such concentrations that the positive properties of the composition are not affected.

Additionally, the novel composition may contain flavouring and sweetening agents, for example peppermint oil, eucalyptus, marjoram, cinnamon, saccharin and the like.

The novel oral composition can be incorporated into lozenges, chewing gum or other products, for example by being stirred into a warm gum material or by coating the exterior surfaces of a chewing gum.

The invention is illustrated by the following Examples.

Example 1: Measurement of the activity of alkaline phosphatase

The activity of alkaline phosphatase is measured using the kinetic colour test for clinical-chemical analytical systems (Olympus System Reagents 800, MIT Serice Inc.; San Diego CA). Instead of the blood usually used, the source of alkaline phosphatase is a solution comprising 200 µl of a suspension of alkaline phosphatase of E. coli (Fluka, CH-9471 Buchs), taken up in 20 ml of 0.1 mol/l tris-HCl buffer, pH 8.0, and prepared with an activity of alkaline phosphatase corresponding to 3 U/ml (U= units), (henceforth called solution (A)).

As measuring solutions, 100 mg of phosphonomethylated chitosan (= P-chitosan) are dissolved in 20 ml of 0.1 mol/l tris-HCl (pH 8.0) and diluted further with 0.1 mol/l each of tris-HCl to 2.5; 0.5; 0.1; 0.05; 0.025; 0.01; 0.0075; 0.005 and 0.0025 mg/ml (solutions B and C).

In order to measure the influence of phosphonomethylated chitosan on the activity of the alkaline phosphatase, 100 µl each of the enzyme solution A are mixed with 900 µl of the dilutions of B or C. According to the clinical-chemical protocol, the activity of the enzyme is determined spectrophotometrically via its ability of degrading the slightly coloured p-nitrophenylphosphate to the intensely coloured p-nitrophenol (see Table 1).

<u>Table 1</u>		
<u>Defined inhibitory concentration</u> <u>[mg/l]</u>	<u>Alk. phosphatase activity [units]</u> <u>phosphonomethylated chitosan</u>	<u>Reference</u> <u>[units]</u>
4536	205	
907.2	104	
453.6	39	
90.72	15.5	
45.36	23	
9.072	41.5	
4.536	73.5	
0.9072	302	
0.4536	302.5	
0.09072	381.5	
blind	1	
reference	—	325.5

These results show that phosphonomethylated chitosan effectively reduces the activity of alkaline phosphatase.

Example 2: Preparation of a toothpaste

<u>Ingredients</u>	<u>% by weight</u>
Distilled water	ad 100
D-glucitol	40.0
Zeodent 113	20.0
glycerol	20.0
tetrasodium pyrophosphate	12.0
disodium pyrophosphate	3.40
sodium lauryl sulfate	1.37
aromatics	1.35
PEG-6	1.33
sodium carboxymethylcellulose	1.00
sodium fluoride	0.50
acrylic acid homopolymer	0.20
saccharin sodium	0.20
titanium dioxide	0.16
P-chitosan	0.03
FD&C Blau CI 42090 (No.1, 1% sol.)	0.03

This toothpaste is very effective against bacterial plaque.

Example 3: Preparation of a mouth wash

<u>Ingredients</u>	<u>Percent by weight</u>
Distilled water	ad 100
ethanol	10.00
glycerol	10.00
PEO-PPO-PEO block polymer	2.00
tetrasodium pyrophosphate	1.50
aromatics	1.35
disodium pyrophosphate	0.50
sodium fluoride	0.50
saccharin sodium	0.3
P-chitosan	0.02

This mouth wash is excellently suitable for prophylaxis against bacterial plaque.

Example 4: Measurement of the adsorption and desorption of microorganisms**a. Adsorption**

Bacteria: *S. mutans* (ZIB6008); *S. mitis* (KL-stab.); *S. anginosus* (ZIB6006) and *S. sanguis* (ZIB6010) are plated out anaerobically on BA plates and incubated. One colony each is allowed to grow to a density of about 0.5 OD₆₆₀ in Todd-Hewitt broth as stock solution.

50mg of hydroxylapatite pearls (HA: Macro-Prep Ceramic Hydroxylapatite, 80micron, of BioRad) are washed once with 1 ml of sterile H₂O and three times with 1ml of absorption buffer sterilised by filtration (5mM KCL, 1mM CCl₂; 0.1mM MgCl₂; 1mM K₂HPO₄, pH 7.2) (cf. Berry & Siragusa (1997); Appl. Environ. Microbiol. 63, 4069-4074). 2ml of the bacterial solution are centrifuged (10,000 rpm, 5 min) and washed twice with adsorption buffer and are then resuspended in 1ml of adsorption buffer containing different concentrations of test substance or no test substance. This solution is combined with the hydroxylapatite pearls suspended in 1 ml of adsorption buffer and incubated, with slight shaking, for 30 min at 37°C. After the HA pearls have sedimented, the supernatant is removed. The HA pearls are dissolved in 1.6 ml of 0.5 N HCl. The optical density (OD₆₆₀) of this solution is determined and is placed in relation to the control containing no test substance prepared for each dilution series (control: 100% adsorption).

b. Desorption

Bacteria: *S. mutans* (ZIB6008); *S. mitis* (KL-stab.); *S. anginosus* (ZIB6006) and *S. sanguis* (ZIB6010) are plated out anaerobically on BA plates and incubated. One colony each is allowed to grow to a density of about 0.5 OD₆₆₀ in Todd-Hewitt broth as stock solution. 50 mg of hydroxylapatite pearls (HA: Macro-Prep Ceramic Hydroxylapatite, 80micron, of BioRad) are washed once with 1 ml of sterile H₂O and three times with 1 ml of absorption buffer sterilised by filtration (5mM KCl, 1mM CCl₂; 0.1mM MgCl₂; 1mM K₂HPO₄, pH 7.2) (cf. Berry & Siragusa (1997); Appl. Environ. Microbiol. 63, 4069-4074). 2 ml of the bacterial solution are centrifuged (10,000 rpm, 5 min) and washed twice with adsorption buffer and are then resuspended in 1 ml of adsorption buffer. This solution is combined with the hydroxylapatite pearls suspended in 1ml of adsorption buffer and incubated, with slight shaking, for 30 min at 37°C. After the HA pearls have sedimented, the supernatant is removed. The HA pearls are washed once with adsorption buffer and are then incubated, with slight shaking, for 30 min at 37°C with 1ml of adsorption buffer containing different concentrations of the test substance. After the HA pearls have sedimented, the supernatant is removed and the HA pearls are dissolved in 1.6 ml of 0.5 N HCl. The optical density (OD₆₆₀) of this solution is determined and is placed in relation to the control containing no test substance prepared for each dilution series (control: 0% desorption).

Results:a. Phosphonomethylated chitosanIn vitro inhibition of the adhesion of microorganisms essential for plaque and tartar formation

<u>Microorganism</u>	<u>P-chitosan [%]</u>	<u>Inhibition+/- [%]</u>	<u>Average error</u>
S. mutans	0.2	76.0	+/- 5.26
	0.02	38.8	+/- 7.16
	0.002	27.0	+/- 4.29
	0.0002	13.4	+/- 4.14
S. mitis	0.2	84.1	+/- 0.97
	0.02	67.8	+/- 3.37
	0.002	27.4	+/- 6.43
	0.0002	7.1	+/- 4.56
S. sanguis	0.200	85.1	+/- 0.81
	0.02	72.7	+/- 4.84
	0.002	43.6	+/- 9.05
	0.0002	35.4	+/- 10.37
S. anginosus	0.200 %	74.3%	+/- 3.78
	0.02 %	43.1%	+/- 10.92
	0.002%	24.8%	+/- 9.67
	0.0002%	8.5%	+/- 1.44

In vitro desorption of adhering microorganisms essential for plaque and tartar formation

<u>Microorganism</u>	<u>P-chitosan [%]</u>	<u>Inhibition+/- [%]</u>	<u>Average error</u>
S. mutans	0.2	87.3	+/- 10.65
	0.02	60.2	+/- 2.93
	0.002	35.9	+/- 5.98
	0.0002	14.7	+/- 8.31
S. mitis	0.2	89.2	+/- 2.06
	0.02	59.4	+/- 7.70
	0.002	30.8	+/- 8.21
	0.0002	17.3	+/- 7.56

b. 1.6-1,3-β-GlucanIn vitro inhibition of the adhesion of microorganisms essential for plaque and tartar formation

<u>Microorganism</u>	<u>1-6 1,3-β-Glucan [%]</u>	<u>Inhibition+/- [%]</u>	<u>Average error</u>
S. mutans	0.2	79.8	+/- 1.68
	0.02	59.3	+/- 1.53
	0.002	41.0	+/- 2.53
	0.0002	27.35	+/- 7.20
S. mitis	0.2	73.1	+/- 2.72
	0.02	46.7	+/- 3.67
	0.002	25.6	+/- 3.09
	0.0002	15.6	+/- 4.77

In vitro desorption of adhering microorganisms essential for plaque and tartar formation


<u>Microorganism</u>	<u>1-6 1,3-β-Glucan [%]</u>	<u>% Desorption</u>	<u>Average error</u>
S. mutans	0.2	79.8	1.68
	0.02	59.3	1.53
	0.002	41.0	2.53
	0.0002	27.35	7.20
S. mitis	0.2	73.1	2.72
	0.02	46.7	3.67
	0.002	25.6	3.09
	0.0002	15.6	4.77

c. N-DicarboxymethylchitosanIn vitro inhibition of the adhesion of microorganisms essential for plaque and tartar formation

<u>Microorganism</u>	<u>N-dicarboxymethyl- chitosan [%]</u>	<u>Inhibition+/- [%]</u>	<u>Average error</u>
S. mutans	0.2	48.9	+/- 8.87
	0.02	19.1	+/- 9.82
	0.002	14.6	+/- 4.60
	0.0002	7.5	+/- 4.60
S. mitis	0.200	42.1	+/- 5.26
	0.02	32.8	+/- 3.38
	0.002	23.43	+/- 2.30
	0.0002	14.5	+/- 8.05


What is claimed is

1. Use of polyanionic and polyanionically-derivatised natural polysaccharides or non-derivatised natural polysaccharides for inhibiting alkaline phosphatase.
2. Use of polyanionic and polyanionically-derivatised natural polysaccharides for inhibiting alkaline phosphatase.
3. Use according to either claim 1 or claim 2, wherein the natural polyanionic polysaccharides are mucopolysaccharides and other polyanionic polysaccharides.
4. Use according to any one of claims 1 to 3, wherein the polyanionic and polyanionically-derivatised natural polysaccharides have a molecular weight of > 5000.
5. Use according to either claim 1 or claim 2, wherein the polyanionically-derivatised natural polysaccharides are derived from dextrans, xanthans and glucans.
6. Use according to any one of claims 1 to 5, wherein the derivatised natural polysaccharides contain phosphate groups, phosphonate groups or methylphosphonate groups.
7. Use according to either claim 1 or claim 2, wherein the natural polysaccharide used is chitin.
8. Use according to claim 1, wherein the natural polysaccharide used is chitosan.
9. Use according to either claim 1, claim 2 or claim 8, wherein the polyanionically-derivatised polysaccharide used is phosphonomethylated chitosan containing repeating units of formula



wherein

R_1 is hydrogen or a radical of formula




R_2 is a radical of formula (1a),

X_1 and X_2 are each independently of the other hydrogen, C_1 - C_5 alkyl or an alkali ion or ammonium ion, and

n is 20 to 4000.

10. Use according to claim 9, which comprises using phosphonomethylated chitosan of formula



wherein

X_1 and X_2 are as defined for formula (1).

11. Use according to either claim 9 or claim 10, which comprises using compounds of formula (1) or (2), wherein

X_1 and X_2 are each independently of the other alkali metal, and

n is 20 to 1000.

12. Use according to claim 1, wherein the non-derivatised natural polysaccharide used is 1,3- β -glucan.


- 17 -

13. An oral composition, which comprises

- (a) 0.01 to 10 % by weight of at least one linear molecularly dehydrated polyphosphate salt, and
- (b) 0.0001 to 5 % by weight of a polyanionic or polyanionically-derivatised natural polysaccharide.

14. A composition according to claim 13, wherein component (a) is hexametaphosphate, tripolyphosphate, pyrophosphate or a mixture of these compounds.

15. A composition according to either claim 13 or claim 14, which additionally comprises as antimicrobial active substance a compound of formula



wherein

- Y is chloro or bromo,
- Z is SO_2H , NO_2 or C_1 - C_4 alkyl,
- r is 0 to 3,
- o is 0 to 3,
- p is 0 or 1,
- m is 0 or 1, and
- n is 0 or 1.

16. Use of the oral composition according to any one of claims 13 to 15 for prophylaxis against or removal of bacterial plaque.

17. Use of the oral composition according to any one of claims 13 to 15 for preventing the adhesion of microorganisms on solid surfaces and for desorbing microorganisms on solid surfaces.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/07999

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K7/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE "CHEMICAL ABSTRACTS" (HOST: STN, Karlsruhe, DE); Abstract 122: 282 249; & JP 07 076 523 A (DAIICHI SEIYAKU CO.) 20 March 1995 XP002102873 see the whole document	1
X	WO 95 30403 A (O. LARM) 16 November 1995 see the whole document	1-17
X	DE 33 43 200 A (LION CORP.) 30 May 1984 see the whole document	1,13-17
X,P	WO 97 48372 A (HERCULES INC.) 24 December 1997 see the whole document	13-17
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

17 May 1999

Date of mailing of the international search report

01/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Glikman, J-F

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/EP 98/07999

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 22310 A (CIBA-GEIGY AG) 24 August 1995 see the whole document -----	1,12
X	EP 0 803 243 A (PFIZER INC.) 29 October 1997 see the whole document -----	13
A	US 5 094 844 A (A. GAFFAR ET AL.) 10 March 1992 -----	13

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/07999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9530403 A	16-11-1995	AU 687560 B	26-02-1998
		AU 2458595 A	29-11-1995
		EP 0758223 A	19-02-1997
		JP 9512818 T	22-12-1997
		SE 9401540 A	05-11-1995
		US 5711938 A	27-01-1998
DE 3343200 A	30-05-1984	JP 59152312 A	31-08-1984
		JP 1731392 C	29-01-1993
		JP 3015604 B	01-03-1991
		JP 59101416 A	12-06-1984
		GB 2132889 A,B	18-07-1984
		US 4512968 A	23-04-1985
WO 9748372 A	24-12-1997	US 5869029 A	09-02-1999
WO 9522310 A	24-08-1995	AU 686327 B	05-02-1998
		AU 1664995 A	04-09-1995
		BR 9506829 A	30-09-1997
		EP 0746307 A	11-12-1996
		GB 2286530 A,B	23-08-1995
		JP 9508909 T	09-09-1997
		NZ 279497 A	24-10-1997
		US 5814341 A	29-09-1998
		ZA 9501320 A	18-08-1995
EP 803243 A	29-10-1997	AU 1905797 A	30-10-1997
		CA 2203319 A	24-10-1997
US 5094844 A	10-03-1992	AT 133853 T	15-02-1996
		AU 649088 B	12-05-1994
		AU 8881491 A	25-06-1992
		CA 2057697 A	21-06-1992
		CN 1062463 A	08-07-1992
		CS 9103994 A	15-07-1992
		DE 69117034 D	21-03-1996
		DE 69117034 T	02-10-1996
		DK 492997 T	24-06-1996
		EP 0492997 A	01-07-1992
		FI 916053 A	21-06-1992
		GR 91100506 A,B	23-11-1992
		HK 71297 A	06-06-1997
		HU 212441 B	28-06-1996
		JP 4275212 A	30-09-1992
		MX 9102665 A	01-06-1992
		NO 180433 B	13-01-1997
		PL 167491 B	30-09-1995
		PT 99817 A	31-12-1992
		SG 48983 A	18-05-1998
		SK 279232 B	05-08-1998
		RU 2092162 C	10-10-1997
		ZA 9109580 A	04-06-1993